Agomab doses first patient in Phase 2b Crohn's disease study

October 13, 2026 4:05 PM

Agomab Therapeutics NV announced that the first patient has been dosed in NOV-ERA, a global Phase 2b study evaluating ontunisertib ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found